Vimarsana
Biggest News Aggregation in the World

Prevention Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Prevention Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Prevention Data Today - Breaking & Trending Today

South Korea intensifies project to warn younger consumers of excessive caffeine consumption risks - Vimarsana News

South Korea intensifies project to warn younger consumers of excessive caffeine consumption risks

The South Korean government is working to expand a pilot project warning consumers of excessive caffeine consumption, with a particular focus on children.

Behavioral Health looking at causes of high youth suicide on Guam - Vimarsana News

Behavioral Health looking at causes of high youth suicide on Guam

Researchers are trying to find out why suicide rates have historically been higher among young people on Guam with the average age of youth suicide attempts and cases now at

Page A1 | e-Edition | guampdn.com - Vimarsana News

Page A1 | e-Edition | guampdn.com

View the Pacific Daily News for Monday, June 13, 2022

Where in Ky. is vaccine resistance highest? New interactive tools can help communities target education and outreach efforts - Vimarsana News

Where in Ky. is vaccine resistance highest? New interactive tools can help communities target education and outreach efforts

University of Washington It's easy to find your locality's coronavirus vaccination rate, but what about its vaccine hesitancy rate, or local interest in vaccination? Two new interactive tools reveal those numbers.   Facebook; the other shows the relative interest in vaccination shown by online searches.    The Facebook-gathered data are in interactive maps from the  University of Washington, showing what counties (and even what Zip codes) are most hesitant to get a shot. The maps by the university's  Institute for Health Metrics and Evaluation reflect answers to this questio...

ACTG announces Camostat will not advance to phase 3 in outpatient treatment study for COVID-19 - Vimarsana News

ACTG announces Camostat will not advance to phase 3 in outpatient treatment study for COVID-19

 E-Mail Los Angeles, Calif. - The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced that the Camostat treatment group of the COVID-19 outpatient treatment study, ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, will not move to phase 3. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple investigational agents for treating early COVID-19 in a single trial. For information about the trial, please visit the study website. Camostat, provided by Sagent Pharmaceuticals (a Nichi-Iko Group Company), is an orally administe...